查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965778

软组织肉瘤市场－全球产业规模、份额、趋势、机会、预测：按治疗类型、最终用户、地区和竞争对手划分，2021-2031年

Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球软组织肉瘤市场预计将从 2025 年的 17.1 亿美元成长到 2031 年的 27.8 亿美元，复合年增长率为 8.44%。

软组织肉瘤是指一群罕见的恶性肿瘤，这些肿瘤发生于脂肪、肌肉、神经和血管等结缔组织。全球软组织肉瘤市场的成长主要受此类疾病发生率上升以及免疫疗法和标靶药物等创新治疗方法快速发展所驱动，这些疗法与传统化疗相比，能显着改善患者的预后。为了凸显疾病的流行程度，美国癌症协会预测，到2025年，美国将新增约13,520例软组织肉瘤病例。

市场概览
预测期 2027-2031
市场规模：2025年 17.1亿美元
市场规模：2031年 27.8亿美元
复合年增长率：2026-2031年 8.44%
成长最快的细分市场 抗血管新生药物
最大的市场 北美洲

儘管取得了这些进展，但尖端生物疗法的高成本仍然是市场发展的重要障碍。各地区严格的报销政策进一步加剧了这一沉重的经济负担，限制了患者获得救命药物的机会，也限制了生产商的产生收入。因此，治疗费用仍然是一个主要挑战，严重限制了有效治疗方法的推广，并可能阻碍全球软组织肉瘤市场的整体成长。

市场驱动因素

免疫疗法和标靶治疗的快速发展正在改变软组织肉瘤的治疗标准，使其不再局限于传统化疗，从根本上改变了全球软组织肉瘤市场。美国食品药物管理局 (FDA) 加速核准Tessella（afamitresgen autoleucel）用于治疗滑膜肉瘤，这标誌着一个重要的里程碑，因为它是第一个针对固态肿瘤设计的基因修饰细胞疗法。这项创新满足了具有特定基因谱的患者的巨大未满足需求，为传统治疗方法失效的领域带来了新的希望。 Adaptive Immune Therapeutics 公司于 2024 年 8 月公布的 SPEARHEAD-1 试验数据显示，在多重抗药性患者中，总缓解率达到 43.2%，显着超过了以往的基准值。这些突破性成果的商业性潜力显而易见。 2024 年 8 月， 自我调整 Immune Therapeutics 预测，其肉瘤治疗业务在美国的年销售额尖峰时段可达约 4 亿美元，凸显了肿瘤学这一细分领域的盈利商机。

同时，全球软组织肉瘤发生率和盛行率的上升是推动市场扩张的主要动力。随着人口老化和诊断能力的提高，这些罕见恶性肿瘤的负担正在稳步加重，亟需更广泛地获得有效治疗，并催生对新疗法的迫切需求。根据2024年5月发表于《柳叶刀》的“2021年全球疾病负担研究”，2021年全球软组织和骨外肉瘤的年发病率达到96,201例，反映了过去30年来疾病负担的持续累积。患者数量的增加将促使製药公司加快临床开发平臺，并鼓励医疗系统将更多资源投入肉瘤专科治疗中，从而推动市场长期持续成长。

市场挑战

先进治疗性介入带来的巨大经济负担是限制全球软组织肉瘤市场成长的主要因素。生物製药和标靶治疗的高昂采集费用往往超出公共和私人保险公司设定的报销限额。这种定价结构导致严格的报销通讯协定和拒付情况，使得相当一部分患者无法获得必要的治疗。根据美国国家癌症研究所预测，到2024年，软组织肉瘤的5年存活率为65.8%。

儘管这项生存指标凸显了持续获得有效治疗的迫切性，但经济障碍却严重阻碍了这种获取。当患者因经济负担（经济毒性）而放弃治疗或选择疗效较差的替代方案时，昂贵治疗方法的市场渗透率将受到严重限制。因此，临床可近性与患者支付能力之间的差距限制了製造商的投资回报，进而影响了全球市场的整体获利能力和商业性扩张。

市场趋势

将人工智慧 (AI) 应用于肉瘤诊断正成为一种变革性趋势，旨在应对组织学异质性这一重大挑战，因为组织学异质性会严重影响准确诊断。先进的演算法正被用于分析电脑断层扫描的放射组学数据，从而实现更精确的肿瘤分级和亚型分类，而无需立即进行侵入性操作。这项技术突破透过促进更早、更准确的干预并降低误诊率，直接影响患者管理策略。正如 2024 年 1 月 RAD 杂誌一篇题为「研究表明，人工智慧比切片检查更能准确地帮助制定罕见肉瘤的个人化治疗方案」的报导中所述，新开发的 AI 演算法在所检查的肉瘤中准确预测了 84% 的疾病类型，在区分复杂亚型方面显着优于标准切片检查方法。

同时，市场正在策略性地转向采用液态生物检体和循环肿瘤DNA（ctDNA）分析，以克服传统组织取样在监测疾病进展方面的限制。这种非侵入性方法能够即时检测分子层面的残留病灶，并识别可治疗的基因组突变，这对于没有復发性驱动突变的亚型尤其重要。根据2024年5月在美国临床肿瘤学会（ASCO）上发表的一篇题为“多重检测液态生物检体方法提高骨和软组织肉瘤的检测准确性”的摘要，在诊断时融合基因阴性的横纹肌肉瘤样本中，100%的样本均成功检测到了循环肿瘤物质，证实了该方法在追踪难以检测的恶性肿瘤方面的高灵敏度。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球软组织肉瘤市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 治疗方法（标靶治疗、化疗、抗血管新生药物、放射线治疗、其他）
    • 依最终使用者（医院、居家医疗、专科医疗中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美软组织肉瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲软组织肉瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区软组织肉瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲软组织肉瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲软组织肉瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球软组织肉瘤市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17108

The Global Soft Tissue Sarcoma Market is projected to expand from a valuation of USD 1.71 Billion in 2025 to USD 2.78 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.44%. Soft tissue sarcomas represent a diverse collection of rare malignancies that originate in connective tissues, including fat, muscle, nerves, and blood vessels. The growth of this global market is largely propelled by the increasing incidence of these conditions and the rapid advancement of innovative therapeutic modalities, such as immunotherapies and targeted drugs, which provide superior patient outcomes compared to conventional chemotherapy. Highlighting the prevalence of the disease, the American Cancer Society projected that approximately 13,520 new cases of soft tissue sarcoma would be diagnosed in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.71 Billion
Market Size 2031USD 2.78 Billion
CAGR 2026-20318.44%
Fastest Growing SegmentAnti-angiogenesis Drugs
Largest MarketNorth America

Despite these advancements, the market faces a substantial obstacle due to the high costs associated with cutting-edge biologic therapies. This significant financial burden, exacerbated by strict reimbursement policies in various regions, restricts patient access to essential life-saving medications and constrains revenue generation for manufacturers. Consequently, affordability remains a critical challenge that could severely limit the broader adoption of effective treatments and hinder the overall expansion of the global soft tissue sarcoma market.

Market Driver

Rapid progress in immunologics and targeted therapies is fundamentally transforming the global soft tissue sarcoma market, shifting treatment standards beyond traditional chemotherapy. A major milestone was achieved with the FDA's accelerated approval of Tecelra (afamitresgene autoleucel) for synovial sarcoma, representing the first engineered cell therapy designed for a solid tumor. This innovation meets significant unmet needs for patients with specific genetic profiles, offering new hope where conventional options have failed. Data from Adaptimmune Therapeutics in August 2024 regarding the 'SPEARHEAD-1' trial indicated an overall response rate of 43.2% among heavily pre-treated patients, significantly outperforming historical benchmarks. The commercial potential of such breakthroughs is evident, with Adaptimmune Therapeutics projecting in August 2024 that its sarcoma franchise could generate approximately $400 million in peak annual sales in the United States, underscoring the lucrative opportunities in this niche oncology sector.

Concurrently, the rising global incidence and prevalence of soft tissue sarcomas act as a primary catalyst for market expansion. As populations age and diagnostic capabilities improve, the identified burden of these rare malignancies continues to increase, necessitating wider access to effective treatments and driving demand for novel therapeutics. According to the Global Burden of Disease Study 2021, published in The Lancet in May 2024, the global annual incidence of soft tissue and extraosseous sarcomas reached 96,201 cases in 2021, reflecting a consistent accumulation of disease burden over the past three decades. This growing patient population compels pharmaceutical developers to accelerate their clinical pipelines and encourages healthcare systems to allocate greater resources toward specialized sarcoma care, thereby sustaining long-term market growth.

Market Challenge

The substantial financial pressure associated with advanced therapeutic interventions constitutes a primary restraint on the growth of the global soft tissue sarcoma market. High acquisition costs for biologic agents and targeted therapies often exceed the coverage limits set by public and private payers. This pricing structure frequently results in strict reimbursement protocols or coverage denials, effectively preventing a significant portion of the patient population from accessing necessary care. According to the National Cancer Institute, the 5-year relative survival rate for soft tissue sarcoma was reported to be 65.8 percent in 2024.

This survival metric highlights the urgent need for consistent access to effective therapies, yet economic barriers significantly disrupt this access. When financial toxicity forces patients to forego treatment or settle for less effective alternatives, the market penetration of premium therapies is severely curtailed. Consequently, the disparity between clinical availability and patient affordability restricts the return on investment for manufacturers, thereby limiting the overall revenue potential and commercial expansion of the global market.

Market Trends

The integration of Artificial Intelligence (AI) into sarcoma diagnostics is emerging as a transformative trend, addressing the critical challenge of histological heterogeneity that often complicates accurate diagnosis. Advanced algorithms are now utilized to analyze radiomic data from CT scans, enabling more precise tumor grading and subtype classification without the immediate need for invasive procedures. This technological leap facilitates earlier and more accurate interventions, directly influencing patient management strategies by reducing misdiagnosis rates. As noted by RAD Magazine in January 2024, in an article titled 'Research shows AI helps tailor treatment for rare sarcomas more accurately than biopsy,' a newly developed AI algorithm accurately predicted the disease type of 84% of tested sarcomas, significantly outperforming the diagnostic accuracy of standard biopsy methods in differentiating between complex subtypes.

Simultaneously, the market is witnessing a strategic shift toward the adoption of liquid biopsy and circulating tumor DNA (ctDNA) analysis to overcome the limitations of traditional tissue sampling in monitoring disease progression. This non-invasive modality allows for the real-time detection of molecular residual disease and the identification of actionable genomic alterations, which is particularly vital for subtypes that lack recurrent driver mutations. According to an abstract from the American Society of Clinical Oncology in May 2024 titled 'A multi-assay liquid biopsy approach to improve detection of bone and soft tissue sarcomas,' circulating tumor material was successfully detected in 100% of fusion-negative rhabdomyosarcoma samples at the time of diagnosis, underscoring the high sensitivity of this approach for tracking hard-to-detect malignancies.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Report Scope

In this report, the Global Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Soft Tissue Sarcoma Market, By Treatment Type

  • Targeted Therapy
  • Chemotherapy
  • Anti-Angiogenesis Drugs
  • Radiation Therapy
  • Others

Soft Tissue Sarcoma Market, By End User

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Soft Tissue Sarcoma Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Soft Tissue Sarcoma Market.

Available Customizations:

Global Soft Tissue Sarcoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Soft Tissue Sarcoma Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others)
    • 5.2.2. By End User (Hospitals, Homecare, Specialty Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Soft Tissue Sarcoma Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Soft Tissue Sarcoma Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Soft Tissue Sarcoma Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Soft Tissue Sarcoma Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User

7. Europe Soft Tissue Sarcoma Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Soft Tissue Sarcoma Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Soft Tissue Sarcoma Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Soft Tissue Sarcoma Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Soft Tissue Sarcoma Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Soft Tissue Sarcoma Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Soft Tissue Sarcoma Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Soft Tissue Sarcoma Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Soft Tissue Sarcoma Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Soft Tissue Sarcoma Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Soft Tissue Sarcoma Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Soft Tissue Sarcoma Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Soft Tissue Sarcoma Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Soft Tissue Sarcoma Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Soft Tissue Sarcoma Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Soft Tissue Sarcoma Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. South America Soft Tissue Sarcoma Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Soft Tissue Sarcoma Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Soft Tissue Sarcoma Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Soft Tissue Sarcoma Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Soft Tissue Sarcoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Viatris Inc
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. Sanofi
  • 15.5. Pfizer Inc.
  • 15.6. GSK plc
  • 15.7. Novartis AG
  • 15.8. Bayer AG
  • 15.9. Sun Pharmaceutical Industries Ltd.
  • 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer